UBS Maintains Buy Rating on Danone with €95 Target Price

Overview

This UBS research report summarizes key takeaways from informal discussions with Danone’s CEO and CFO, expressing optimism about the company’s outlook. The report reaffirms a Buy rating with a 12-month target price of €95, representing 54.8% upside from the current share price.

Core views

Management’s responses to key concerns were reassuring. The 2026 guidance has been reaffirmed, with Q1 results affected by one-off factors. The North American EDP business (including cream, yogurt, and Silk brands) is improving sequentially, with expectations for continued performance recovery in the U.S. Early Life Nutrition in China is expected to sustain growth, despite a nearly 50% decline in birth numbers, as the market value remains stable at €20 billion. The infant formula recall is not expected to have significant or lasting impact, and the company is investing to rebuild brand trust. In Adult Medical Nutrition, market trends favor Danone, with rapid growth in Europe and Asia. Cost-saving initiatives are performing strongly, enabling pricing actions to remain as limited and selective as possible. Driving volume-led growth is the priority for 2026. Despite slightly higher inflation, pricing and cost savings should support achieving targets (3–5% organic sales growth, with operating profit outpacing sales).

Analysis framework

UBS employs a DCF valuation methodology, assuming a WACC of 7.5% (based on a 3% risk-free rate and a 6% equity risk premium) and a terminal growth rate of 2.0%. The report analyzes the performance and outlook of Danone’s business segments: Essential Dairy & Plant-based (54% of sales), Specialized Nutrition (30%), and Waters (16%). Particular attention is given to dynamics in North America and China, as well as cost-saving and pricing strategies.

Methodology notes

• Valuation MethodDCF Discounted Cash Flow

  Valuation using DCF model

  The report uses a DCF approach to value Danone by forecasting future free cash flows and discounting them to present value, a core method in equity valuation.

• Company Fundamentals & Financial FrameworkROIC–WACC spread

  Focus on the difference between return on invested capital and cost of capital

  The report implicitly analyzes Danone’s ROIC relative to its WACC, a key metric for assessing a company’s ability to create value.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Danone (DANO.PA)

  Benefits from cost-saving initiatives and improvements in North America and China

  Strengths

  Diversified portfolio, strong brand portfolio, leadership position in Specialized Nutrition

  Weaknesses

  European dairy may face pricing pressure and accelerated commoditization

  Risks

  Further declines in birth rates in key markets like China could affect Specialized Nutrition growth

Key data

• 2026 Target Organic Sales Growth3-5%Operating profit expected to outpace sales growth
• Chinese Infant Formula Market Size€20bnMarket value stable despite nearly 50% decline in birth numbers
• Current Share Price (June 1, 2026)€61.36Target price implies 54.8% upside
• DCF Model Assumption: WACC7.5%Based on 3% risk-free rate and 6% equity risk premium

Impact & implications

The report believes Danone can navigate inflationary pressures through cost savings and pricing strategies to achieve its growth targets. Continued improvement in North America and China will support performance, while structural growth trends in Specialized Nutrition provide long-term momentum.

Risks

• Potential pricing erosion and accelerated commoditization in European dairy
• Further birth rate declines in key markets (e.g., China) could impact Specialized Nutrition growth
• Foreign exchange volatility affecting euro-denominated reported results

What to watch

• Quarterly progress in North American EDP business
• Growth trajectory of Early Life Nutrition in China
• Execution effectiveness of cost-saving initiatives